Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Autologous SIRPα-low Macrophages (SIRPant-M) Administered by IT- Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416 is registered in ClinicalTrials.gov with SIRPant Immunotherapeutics, Inc. as lead sponsor.

NCT NCT05967416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05967416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Autologous SIRPα-low Macrophages (SIRPant-M) Administered by IT- Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lead sponsor
SIRPant Immunotherapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 17, 2024
Completion date
December 31, 2025
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refractory non-hodgkin lymphoma, relapsed non-hodgkin lymphoma